Pfizer tests experimental drug to slow stomach emptying in obesity
NCT ID NCT07508241
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tests an experimental drug called PF-08653944 in 20 overweight or obese adults. Researchers want to see how it affects the speed at which the stomach empties food, using a common painkiller as a marker. The main goals are to understand the drug's effects and check for side effects, which could help plan larger future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PF-08653944 (also called MET097)
What this could lead to
If successful, this study could help researchers understand how PF-08653944 affects digestion, potentially guiding future treatments for weight management.
What could go wrong
This is a very early Phase 1 trial with only 20 participants, so results may not apply broadly. The medicine may cause side effects or fail to show meaningful effects on stomach emptying.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pfizer Clinical Research Unit - New Haven
RECRUITINGNew Haven, Connecticut, 06511, United States